The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the ...
About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the ...
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization ...
After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec ...
This release fulfills the Company's October 20 announcement that next-round results on the expanded human-submitted dataset ...
Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize ...
Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in ...
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary ...
In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, ...
November 2, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading ...
Bioscience employment rose in 41 states, though not in California, according to a new report from the Biotechnology ...
In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results